SNDX Stock Summary and Trading Ideas (Syndax Pharmaceuticals | NASDAQ:SNDX)

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals trades on the NASDAQ stock market under the symbol SNDX.

As of June 4, 2026, SNDX stock price declined to $18.02 with 5,485,054 million shares trading.

SNDX has a beta of 0.09, meaning it tends to be less sensitive to market movements. SNDX has a correlation of 0.00 to the broad based SPY ETF.

SNDX has a market cap of $1.60 billion. This is considered a Small Cap stock.

Last quarter Syndax Pharmaceuticals reported $65 million in Revenue and -$.48 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.11.

In the last 3 years, SNDX traded as high as $25.59 and as low as $8.58.

The top ETF exchange traded funds that SNDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

SNDX has outperformed the market in the last year with a return of +61.0%, while the SPY ETF gained +28.2%. However, in the most recent history, SNDX shares have underperformed the stock market with its stock returning -15.8% in the last 3 month period and -10.5% for the last 2 week period, while SPY has returned +11.5% and +2.1%, respectively.

SNDX support price is $17.80 and resistance is $18.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNDX shares will trade within this expected range on the day.